logo
Lung cancer survival rate has doubled, but it still causes the most cancer deaths: StatCan

Lung cancer survival rate has doubled, but it still causes the most cancer deaths: StatCan

Yahoo13 hours ago
TORONTO — Five-year survival rates for people with lung cancer have doubled since the 1990s, but the disease still kills more patients than any other type of cancer, a Statistics Canada report said on Wednesday.
The report said the number of people living five years after they were diagnosed jumped from 13 per cent to 27 per cent between 1992 and 2021.
Lung cancer is still responsible for almost a quarter of all cancer deaths in Canada, it said.
The report attributed the increase in lung cancer survival to new treatments, including drugs that target specific molecules in cancer cells and immunotherapy that prompts the patient's immune system to attack cancerous cells.
"Back in the 1990s, getting a lung cancer diagnosis, it truly was a bit of a death sentence," said Jessica Moffatt, vice-president of programs and advocacy at the Lung Health Foundation in an interview about the StatCan findings.
"Cancer was detected very late, so usually around stage four, and the likelihood of survival was very low."
Moffatt agreed that more effective treatments are part of the reason for increased lung cancer survival rates, but also said that better screening has been vital.
"What we're seeing today is that we're able to detect cancer earlier, where treatment is more likely to be effective," she said.
Moffatt expects to see five-year survival rates climb higher than StatCan's 2021 data show, following the introduction of organized lung cancer screening programs in Ontario, British Columbia and Nova Scotia in 2022.
Those programs screen patients for risk factors such as age and smoking history and if they're deemed high-risk, they are told to get a referral for a low-dose CT scan from a family doctor or nurse practitioner.
Depending on the results of that "baseline scan," Moffatt said, patients come back for regular screenings or are referred to diagnostic assessment if scan suggests lung cancer might be present.
She expects to see the survival rate trend upward as more provinces fund lung cancer screening programs.
"One of the common stories we hear is that somebody had a persistent cough, they would go to their family physician who had potentially prescribed antibiotics and they would go back home and that wouldn't work so they go to the ER (and) get more antibiotics and time was just passing when the lung cancer, the tumour was growing," Moffatt said.
"Then when they finally got their diagnosis, it's at such an advanced stage. And that's where organized screening tries to reduce the likelihood of that story because the most at-risk people should be screened frequently enough to catch any cancer growth."
The Statistics Canada report said that as of 2021, the cancers with a five-year survival rate of 90 per cent or higher include thyroid, testicular, prostate and breast cancers, as well as melanoma skin cancer.
It says cancers with the lowest survival rates of under 10 per cent include mesothelioma — cancer in the membrane that surrounds most internal organs — as well as cancer in the bile ducts of the liver.
The report says those cancers, along with pancreatic cancer, are often diagnosed at advanced stages when the cancer has already spread.
StatCan gathered the data on cancer survival rates from its Canadian Cancer Registry as well as its Canadian Vital Statistics death database.
This report by The Canadian Press was first published Aug. 13, 2025.
Canadian Press health coverage receives support through a partnership with the Canadian Medical Association. CP is solely responsible for this content.
Nicole Ireland, The Canadian Press
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Recombinant Human Hair Keratin Protein Market 2025 Trends and Updates
Recombinant Human Hair Keratin Protein Market 2025 Trends and Updates

Yahoo

time23 minutes ago

  • Yahoo

Recombinant Human Hair Keratin Protein Market 2025 Trends and Updates

The global recombinant human hair keratin protein market is growing quickly as more people seek effective hair health solutions and advanced wound healing treatments, says a study published by Towards Healthcare a sister firm of Precedence Research. Ottawa, Aug. 14, 2025 (GLOBE NEWSWIRE) -- The global recombinant human hair keratin protein market is on a strong growth trajectory, with revenues expected to climb into the hundreds of millions by 2034. This momentum is being fueled by a rising focus on hair health, a noticeable increase in bleeding disorder cases, and a wave of fresh investments pouring into biotechnology. Together, these factors are creating fertile ground for innovation and demand across multiple industries. Companies in North America, Asia-Pacific, and Europe are actively investing in research, driving innovations, and forming partnerships to open new market opportunities. The Complete Study is Now Available for Immediate Access | Download the Sample Pages of this Report @ Key Takeaways North America dominated the recombinant human hair keratin protein market in 2024. Asia Pacific is estimated to grow at the fastest CAGR during the forecast period. Market Overview & Potential Recombinant human hair keratin protein is a lab-engineered protein that replicates the structure and function of natural keratin in human hair. It is produced via recombinant DNA technology, resulting in a highly controlled and pure form of keratin that differs from traditional extracts. This makes it a valuable material for applications such as wound healing and hair care. Conventional keratin extraction methods can be inconsistent and may not yield pure products, whereas recombinant production ensures greater purity and enables precise control over the protein's amino acid sequence and structure, resulting in more predictable properties. Top Countries in Recombinant Human Hair Keratin Protein Market: United States Contribution: Leading the global market with strong demand for medical-grade recombinant keratin, supported by a robust biotech ecosystem and healthcare infrastructure. Strength: Advanced R&D capabilities and regulatory support for therapeutic and regenerative applications. China Contribution: Fastest-growing market, fueled by a rapidly expanding cosmetics and personal care sector. Strength: Strong domestic production capabilities, rising consumer awareness, and increasing investment in biotech innovations. Germany Contribution: Key contributor in Europe, especially in high-purity recombinant keratin for medical and cosmetic formulations. Strength: Expertise in biotechnology and demand for premium, high-performance personal care products. France Contribution: Strong market for cosmetic applications, particularly in haircare and skincare products incorporating natural bioactive ingredients. Strength: Sophisticated beauty industry and preference for sustainable, biologically derived ingredients. India Contribution: Emerging player in both medical and cosmetic applications of recombinant keratin. Strength: Large population base, rising demand for advanced hair and skin treatments, and growing domestic manufacturing activity. You can place an order or ask any questions, please feel free to contact us at sales@ What is the Growth Potential Responsible for The Growth of The Recombinant Human Hair Keratin Protein Market? The growth of the market is driven by the growing application in the biomedical field due to its biocompatibility, ability to promote cell growth, and biodegradability, which makes it ideal for various medical uses, driving the growth. The key applications, like tissue regeneration, drug delivery systems, and wound healing, are supporting the growth of the market. Other key drivers are biotechnology research due to the growing biotechnology sector, in personal care and cosmetics, and sustainable and ethical sourcing. Increasing incidence of chronic diseases, and government initiatives in R&D in life sciences research and development. What Are the Growing Trends Associated with the Recombinant Human Hair Keratin Protein Market? The technological advancements like innovation in synthetic biology and demonstration technology for the development of new and tailored properties, and more efficient production methods. Rising demand in the cosmetic sector for the development of hair care products for improving the shine, strengthening the damaged hair, and reducing the frizz increases the demand for the product. The growing biomedical applications, like in wound healing, tissue engineering, and drug delivery, fuel the demand for the product, supporting the growth. Shift towards sustainable and ethical products, like growing demand and interest in vegan and plant-based keratins, improves the market growth of the market. Increasing awareness and adoption due to the benefits offered and availability of the products make it a preferred choice, and increase the growth. What Is the Growing Challenge in the Recombinant Human Hair Keratin Protein Market? However, the recombinant human hair keratin protein market faces challenges including production issues, consistency concerns, and consumer perceptions. Although recombinant technology provides advantages like higher purity and specific amino acid composition, it also risks problems like misfolding, aggregation, and low yields. Additionally, high production costs, especially due to specialized equipment and chemicals, can hinder market growth. Consumer preferences for natural or plant-based products, along with safety and efficacy concerns regarding keratin treatments, could also limit market expansion. Get the latest insights on life science industry segmentation with our Annual Membership: Regional Analysis How Did North America Dominate the Recombinant Human Hair Keratin Protein Market in 2024? North America led the recombinant human hair keratin protein market in 2023. Growth is driven by increased investments, collaborations, key industry players, and advanced R&D activities. The US and Canada are the primary markets, with companies like Novus Biologicals, Abcam Ltd., PROGEN, and OriGene contributing significantly. US government initiatives to promote biotech research further boost the market, complemented by over 130 recombinant proteins approved by the US FDA for clinical use. In the UK, industries are exploring innovative methods to enhance hair growth, quality, and reduce hair fall using recombinant human hair keratin protein. Additionally, rising awareness about hair health is fueling demand for these products. What Made Asia Pacific Significantly Grow in The Recombinant Human Hair Keratin Protein Market in 2024? Asia-Pacific is expected to grow the fastest in the recombinant human hair keratin protein market during the forecast period. Market growth is driven by increasing research and development activities, rising government funding, a growing number of bleeding disorder cases, favorable infrastructure, and lower costs. Recombinant keratin has been shown to promote skin wound healing and improve blood clotting. In China, about 65,000 people suffer from hemophilia, while India has the second-largest number of hemophilia cases worldwide, with 136,000 patients. The demand for products that support hair growth and reduce hair loss is rapidly increasing in China, South Korea, and Japan. Companies like Tsubaki use recombinant human keratin to develop luxurious hair treatments that attract beauty-conscious consumers. Become a valued research partner with us - Recent Developments In July 2024, Yuhan Corp, a South Korean pharmaceutical company, signed a comprehensive R&D collaboration agreement with ProGen. The collaboration was made to strengthen next-generation biologics and drug development research. In April 2024, Bio-Techne Corporation announced a strategic distribution agreement with Thermo Fisher Scientific. The agreement will distribute Bio-Techne's innovative products, such as antibodies, proteins, immunoassay kits, reagents, and enzymes, to laboratories and research institutions across Europe. Browse More Insights of Towards Healthcare: The global GMP grade cytokines market is valued at USD 2.54 billion in 2024, expected to rise to USD 2.79 billion in 2025, and anticipated to reach approximately USD 6.48 billion by 2034. This represents a steady growth trajectory at a CAGR of 9.84% from 2025 to 2034. The global recombinant proteins market is estimated at USD 3.36 billion in 2025 and is forecasted to climb to around USD 8.08 billion by 2034, expanding at a CAGR of 10.24% over the forecast period. The recombinant lysyl endopeptidase market was valued at USD 38 million in 2023 and is projected to reach USD 67.06 million by 2034, growing at a CAGR of 5.3% between 2024 and 2034. The global hair transplant market stands at USD 7.33 billion in 2024, rising to USD 8.87 billion in 2025, with projections indicating a surge to nearly USD 49.44 billion by 2034—signaling rapid expansion. The hair treatment drug market was worth USD 1.4 billion in 2023 and is anticipated to grow to USD 2.99 billion by 2034, recording a CAGR of 7.14% during 2024–2034. The global host cell protein testing market is valued at USD 2.37 billion in 2024, estimated to increase to USD 2.56 billion in 2025, and forecasted to hit USD 5.19 billion by 2034, with an expected CAGR of 8.17% from 2025 to 2034. The global protein expression technology market is pegged at USD 2.85 billion in 2024, projected to rise to USD 3.05 billion in 2025, and likely to reach USD 5.58 billion by 2034, reflecting a CAGR of 6.94% over the forecast timeline. The global proteinase K market is valued at USD 4.82 billion in 2024, forecasted to grow to USD 5.23 billion in 2025, and set to reach USD 10.93 billion by 2034, advancing at a CAGR of 8.54% between 2025 and 2034. The global cell-free protein expression market is valued at USD 315.03 million in 2024, expected to grow to USD 342.25 million in 2025, and projected to hit USD 716.26 million by 2034, expanding at a CAGR of 8.63% from 2025 to 2034. The global protein therapeutics market is calculated at USD 375.3 billion in 2024, projected to grow to USD 401.89 billion in 2025, and expected to reach USD 740.07 billion by 2034, advancing at a CAGR of 7.08% over the forecast period. Recombinant Human Hair Keratin Protein Market Key Players Abcam Limited Abbexa, Ltd. Bon Opus Biosciences Creative Diagnostics MyBioSource, Inc. Novus Biologicals OriGene PROGEN ProSpec Wuhan Huamei Biotech Co., Ltd. Regions Covered North America U.S. Canada Asia Pacific China Japan India South Korea Thailand Europe Germany UK France Italy Spain Sweden Denmark Norway Latin America Brazil Mexico Argentina Middle East and Africa (MEA) South Africa UAE Saudi Arabia Kuwait Access our exclusive, data-rich dashboard dedicated to the healthcare market - built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway. Access the Dashboard: Immediate Delivery Available | Buy This Premium Research @ About Us Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics, with a strong emphasis on life science research. Dedicated to advancing innovation in the life sciences sector, we build strategic partnerships that generate actionable insights and transformative breakthroughs. As a global strategy consulting firm, we empower life science leaders to gain a competitive edge, drive research excellence, and accelerate sustainable growth. You can place an order or ask any questions, please feel free to contact us at sales@ Europe Region - +44 778 256 0738 North America Region - +1 8044 4193 44 Web: Find us on social platforms: LinkedIn | Twitter | InstagramError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Record-breaking birth: This baby was born from an embryo frozen 30 years ago
Record-breaking birth: This baby was born from an embryo frozen 30 years ago

News24

time35 minutes ago

  • News24

Record-breaking birth: This baby was born from an embryo frozen 30 years ago

It sounds like something out of a sci-fi film – an embryo frozen in time for three decades, waiting for the right moment to live – but this isn't a make-believe story. This is the extraordinary story of Thaddeus Daniel Pierce, who's made headlines as the 'oldest' baby ever born. The little boy developed from an embryo that had been frozen for over 30 years, and his parents, Lindsey (35) and Tim Pierce (34) from Ohio in the USA, are embracing this extraordinary journey. 'We had a rough birth, but we are both doing well now,' Lindsey says. 'He is so chill. We are in awe that we have this precious baby.' In the early 1990s Linda Archerd (now 62) had struggled with infertility for six years. In May 1994, she and her then-husband created four embryos through IVF. One embryo resulted in a healthy baby girl, now 30, who has a 10-year-old daughter. The remaining three embryos were frozen and stored for decades; and Linda paid annual storage fees of around $1000. 'I called them my three little hopes,' Linda told Technology Review. READ MORE | 'It was like a little miracle' – Mrs SA on her emotional journey to parenthood When Linda was divorced, she won custody of the embryos but faced a dilemma when she went through menopause. No longer able to carry a pregnancy herself, she had to decide what to do with her remaining embryos. Rather than discarding them or donating anonymously, she chose to donate them through a program that would allow her to connect with the potential parents. 'It's my DNA, it came from me . . . and it's my daughter's sibling,' she explained. The Pierces found Linda's embryo through the Rejoice Fertility Centre's Open Hearts program, an initiative which focuses on older embryos that might otherwise be overlooked. 'We just decided, why not? We'll give them a chance,' Lindsey told News Nation. 'We believe in life at conception, so we'll just give it a chance and see what happens.' Now the first-time mom can't help but feel the timing was perfect. 'I think God had him in store for us. He held him on reserve just for us.' The situation has created some mind-bending family relationships. Linda's biological daughter is technically Thaddeus' sister. 'The baby has a 30-year-old sister,' Linda says. 'It's been pretty surreal. It's hard to even believe.' READ MORE | Cape Town mom welcomes miracle baby after 8 rounds of IVF and heartbreaking loss The Pierces haven't yet met Linda, but hope to connect once they've recovered from the newborn phase. 'We've been in contact with her since the beginning, and we hope to meet her one day,' Lindsey says. Meanwhile, the couple has launched a GoFundMe campaign to cover medical expenses and create an education fund for their little record breaker. 'His story has already reached international headlines and caused quite a stir in the scientific community,' Tim wrote in the fundraiser statement. 'We know he has greater things in store for him than he has already accomplished.'

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store